Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
325.8 GBX | +1.12% | +9.18% | +1.24% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 03 | FTSE 100 gets boost as investors eye rate cuts | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.22 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.93 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Leisure & Recreation
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.24% | 1.84B | C+ | ||
+3.18% | 122B | C | ||
+47.99% | 34.08B | C- | ||
-26.52% | 14.96B | C | ||
+54.70% | 7.83B | D+ | ||
+47.16% | 6.28B | C+ | ||
-15.65% | 3.55B | D+ | ||
+3.39% | 2.99B | C | ||
+13.49% | 2.14B | C+ | ||
+6.30% | 2.01B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TRN Stock
- Ratings Trainline Plc